Kancera: Positive pre-IND feedback from the FDA - Redeye
Bildkälla: Stockfoto

Kancera: Positive pre-IND feedback from the FDA - Redeye

Redeye comments on this morning’s news that Kancera has received positive feedback on the planned clinical program for KAND567 in ST-elevation myocardial infarction.

Redeye comments on this morning’s news that Kancera has received positive feedback on the planned clinical program for KAND567 in ST-elevation myocardial infarction.
Börsvärldens nyhetsbrev